Prescient Therapeutics
Live Investor Briefing
Please join us for a special investor briefing with Prescient Therapeutics CEO and Managing Director Steven Yatomi-Clarke.
In this special one off session, Steven will introduce this unique moment in the companies timeline and outline
- Introduction to the exciting CAR-T field, and Prescient’s role in the recent collaboration with Carina Biotech in developing CAR-T Therapies
- Encouraging clinical trial results of the PTX-200 treatment in Breast Cancer, ovarian cancer and Acute Myeloid Leukemia
- The company’s focuses for 2020
- Increasing growth within the personalised medicines industry
This session is live and interactive, and will include a Q&A session at the end. Spots are limited, so secure yours today